Real-World Evidence of Diagnostic Testing for Driver Oncogene Mutations in Lung Cancer in Japan [0.03%]
日本肺癌诊断检测驱动致癌基因突变的真实世界证据
Yasushi Yatabe,Yasumasa Yoshiki,Koichi Matsumura et al.
Yasushi Yatabe et al.
Introduction: Diagnostic testing is important in determining appropriate treatment for individuals with lung cancer. In 2018, testing of five biomarkers (EGFR, ALK, ROS1, BRAF, programmed cell death-ligand 1 [PD-L1]) was ...
Clinical Efficacy and Safety of Nivolumab in Japanese Patients With Malignant Pleural Mesothelioma: 3-Year Results of the MERIT Study [0.03%]
Nivolumab在日本恶性胸膜间皮瘤患者中的临床疗效和安全性：MERIT研究的三年结果
Nobukazu Fujimoto,Morihito Okada,Takashi Kijima et al.
Nobukazu Fujimoto et al.
Introduction: We examined the long-term efficacy and safety of nivolumab, a human monoclonal antibody that inhibits interactions between the programmed cell death protein-1 receptor and its ligands (programmed death-ligan...
Toshio Fujino,Tetsuya Mitsudomi
Toshio Fujino
Differential Pattern of Resistance and Sensitivity to Different Classes of MET Inhibitors for MET-Amplified Tumors With MET-D1228X or MET-Y1230X Mutations [0.03%]
具有MET-D1228X或MET-Y1230X突变的MET扩增肿瘤对不同类别MET抑制剂的耐药性和敏感性差异模式
Andrew J Piper-Vallillo,Susumu S Kobayashi,Daniel B Costa
Andrew J Piper-Vallillo
Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis [0.03%]
艾瑞替尼对初治的携带ALK重排基因的亚洲晚期非小细胞肺癌患者的疗效及安全性研究：来自ASCEND-4亚组分析的结果
Daniel S W Tan,Sarayut Geater,Chong-Jen Yu et al.
Daniel S W Tan et al.
Introduction: In the phase 3 ASCEND-4 study, ceritinib exhibited improved progression-free survival (PFS) by Blinded Independent Review Committee (BIRC) assessment versus the standard first-line chemotherapy in patients w...
BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib [0.03%]
EGFR突变型接受吉非替尼单一治疗或与奥拉帕利联合治疗的NSCLC患者中BRCA1表达量与其预后的关系
Niki Karachaliou,Oscar Arrieta,Ana Giménez-Capitán et al.
Niki Karachaliou et al.
Introduction: DNA repair capacity, as exemplified by BRCA1 gene expression, is related with outcome to EGFR tyrosine kinase inhibitors in patients with EGFR-mutant NSCLC. Olaparib, a PARP inhibitor, reduces BRCA1 expressi...
Prognostic Impact of Single and Multiple Descriptors in Pathologically Staged T3N0M0 NSCLC [0.03%]
T3N0M0期病理分期的非小细胞肺癌单个和多个预后指标的影响
Takefumi Komiya,Emily Powell,Shinkichi Takamori
Takefumi Komiya
Introduction: T components of the current eighth edition of lung cancer American Joint Commission on Cancer (AJCC) staging assignment include size of primary tumor and others such as chest wall invasion. The role of the p...
Circulating Tumor DNA as a Biomarker of Radiographic Tumor Burden in SCLC [0.03%]
循环肿瘤DNA作为SCLC放射性肿瘤负担的生物标志物
Jarrod T Smith,Aneri Balar,Dhairya A Lakhani et al.
Jarrod T Smith et al.
Introduction: Blood-based next-generation sequencing assays of circulating tumor DNA (ctDNA) have the ability to detect tumor-associated mutations in patients with SCLC. We sought to characterize the relationship between ...
Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Kras Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan [0.03%]
东亚人群中非鳞状NSCLC伴Kras突变患者的预后特征和免疫治疗反应：来自台湾单中心队列研究
Shang-Gin Wu,Wei-Yu Liao,Kang-Yi Su et al.
Shang-Gin Wu et al.
Introduction: Kras mutation is the most common driver oncogene present in patients with NSCLC. Recently, the precision medicine for patients with Kras-mutated NSCLC has been under investigation, but the best treatment is ...
Identification of Novel CDH1-NRG2 α and F11R-NRG2α Fusions in NSCLC Plus Additional Novel NRG2α Fusions in Other Solid Tumors by Whole Transcriptome Sequencing [0.03%]
全转录组测序在非小细胞肺癌及其它实体瘤中鉴定新型CDH1-NRG2 α 和F11R-NRG2α 融合及其他新型的NRG2α 融合基因
Sai-Hong Ignatius Ou,Joanne Xiu,Misako Nagasaka et al.
Sai-Hong Ignatius Ou et al.
Introduction: A novel CD74-NRG2α fusion has recently been identified in NSCLC. We surveyed a large tumor database comprehensively profiled by whole transcriptome sequencing to investigate the incidence and distribution o...